[Zygomycetes and zygomycosis in the new era of antifungal therapies].
Zygomycosis or mucormycosis is the third most invasive fungal infection after candidiasis and aspergillosis. Traditionally, it has been considered a community-acquired disease, but it is becoming a frequent nosocomial-acquired disease. Recently, several publications from different institutions have reported an increase in the number of cases of invasive zygomycosis as a result of the new antifungal and immunosuppresive therapies and the emerging immunocompromised population. In addition, the diagnosis of zygomycosis is elusive, mainly in pulmonary and disseminated forms. One of the main limitations in isolating Zygomycetes from clinical samples is the interpretation of results. The increasing number of invasive fungal infections caused by multiresistant fungi has led to the development of new antifungal drugs with variable activity against Zygomycetes.
Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
M
M
Torres-Narbona
J
J
Guinea
P
P
Muñoz
E
E
Bouza
D000935:Antifungal Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D005658:Fungi / Q000302:isolation & purification / Q000472:pathogenicity; D008826:Microbial Sensitivity Tests; D012307:Risk Factors; D020096:Zygomycosis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*
D000935:Antifungal Agents